Tocopherol

證據等級: L5

預測適應症: 10 個

Tocopherol: From Vitamin E Supplementation to Sclerosing Cholangitis

One-Sentence Summary

Tocopherol (Vitamin E) has no confirmed original indication on record in the available data, and it is not currently marketed or registered in South Africa. The TxGNN model predicts a possible association with Sclerosing Cholangitis, but this is currently supported by only 1 clinical trial (a non-interventional biomarker study) and 1 observational publication, indicating a very early, largely theoretical signal rather than an established therapeutic direction.

Quick Overview

Item	Content
Original Indication	No formal indication on record (Tocopherol/Vitamin E; no SAHPRA licenses exist to reference)
Predicted New Indication	Sclerosing Cholangitis
TxGNN Prediction Score	98.84%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for tocopherol is not available in this evidence pack. Based on known information, tocopherol is the active form of vitamin E, a fat-soluble antioxidant whose established use is correcting vitamin E deficiency; its efficacy as a treatment for any specific disease indication is not documented here, and mechanistically its relevance to sclerosing cholangitis rests on an indirect, deficiency-correction rationale rather than a disease-modifying one.

Sclerosing cholangitis is a chronic cholestatic liver disease that is commonly accompanied by malabsorption of fat-soluble vitamins (A, D, E, K) and by increased oxidative stress. On this basis, tocopherol supplementation could theoretically help correct a secondary vitamin E deficiency and provide adjunctive antioxidant support in these patients.

However, the evidence itself characterizes this link as weak: supplementing tocopherol addresses a downstream consequence of cholestasis (fat malabsorption) rather than the underlying biliary inflammatory/fibrotic process that drives sclerosing cholangitis. It should therefore be regarded as a supportive nutritional measure at most, not a disease-modifying therapy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05582447	N/A	Active, not recruiting	40	Pilot study measuring red blood cell osmotic fragility/deformability in pediatric patients with cholestatic liver disease (including primary sclerosing cholangitis, biliary atresia, Alagille syndrome, etc.); a biomarker observational study, not a tocopherol interventional efficacy trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10735930	2000	Observational	Alimentary Pharmacology & Therapeutics	Plasma antioxidant levels, including vitamin E, are reduced in chronic cholestatic liver disease, consistent with fat-soluble vitamin malabsorption; oxygen-derived free radicals are suggested to contribute to chronic liver damage

South Africa Market Information

Tocopherol currently has no SAHPRA product registrations on record (0 licenses) and is not marketed in South Africa. No dosage forms, brand names, or approved indication text are available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence level is L4 (decision stage S0) — supported only by a non-interventional pediatric biomarker study and a single observational paper, with no direct interventional evidence that tocopherol treats sclerosing cholangitis. The mechanistic rationale is explicitly assessed as weak (deficiency correction, not disease modification), and the drug has zero SAHPRA registrations, meaning there is no local regulatory foundation to build on.

To proceed, the following is needed:

SAHPRA-approved Professional Information / warnings and contraindications (currently a Blocking data gap — DG001), required before any S1 safety screening
Confirmed mechanism of action data for tocopherol (High-severity gap — DG002)
Direct interventional trial evidence specifically testing tocopherol in sclerosing cholangitis (current trial is an observational biomarker study only)
A regulatory pathway/registration assessment if market entry in South Africa is being considered
Given the weak evidence for sclerosing cholangitis specifically, consider evaluating other TxGNN-predicted indications for this drug with stronger evidence — notably rheumatoid arthritis (L2, active Phase 2/3 RCT NCT06915701 directly testing α-tocopherol) and peripheral vascular disease (L2) — as potentially more promising candidates for further work
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.